Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2022 Filed May 3, 2022 19:39 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055428 · tm2214297-3_4seq1.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168 Underlying: Common Stock · 2,168 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 19:39 UTC |
Fiedler SusanneChief Commercial Officer
|
Tax withholdingCommon Stock | 1,019 | $32.33 | $32,944.27 |
DisclosureSEC source: 0001104659-22-055428 · tm2214297-3_4seq1.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,689 Read SEC document |
| May 01, 2022 Filed May 3, 2022 19:39 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionCommon Stock | 2,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055428 · tm2214297-3_4seq1.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:42 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
Exercise / conversionRestricted Stock Units · Derivative | 974 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055433 · tm2214297-7_4seq1.xml · derivative · entry 3 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974 Underlying: Common Stock · 974 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:42 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
Tax withholdingCommon Stock | 334 | $32.33 | $10,798.22 |
DisclosureSEC source: 0001104659-22-055433 · tm2214297-7_4seq1.xml · nonDerivative · entry 2 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,303 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:42 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
Exercise / conversionCommon Stock | 974 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055433 · tm2214297-7_4seq1.xml · nonDerivative · entry 1 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055432 · tm2214297-6_4seq1.xml · derivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812 Underlying: Common Stock · 812 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 279 | $32.33 | $9,020.07 |
DisclosureSEC source: 0001104659-22-055432 · tm2214297-6_4seq1.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,226 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055432 · tm2214297-6_4seq1.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:41 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionRestricted Stock Units · Derivative | 1,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055431 · tm2214297-5_4seq1.xml · derivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490 Underlying: Common Stock · 1,490 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:41 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 425 | $32.33 | $13,740.25 |
DisclosureSEC source: 0001104659-22-055431 · tm2214297-5_4seq1.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:41 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionCommon Stock | 1,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055431 · tm2214297-5_4seq1.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:40 UTC |
Milligan SandraHead of Research & Development
|
Exercise / conversionRestricted Stock Units · Derivative | 1,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055430 · tm2214297-4_4seq1.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,896 Underlying: Common Stock · 1,896 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:40 UTC |
Milligan SandraHead of Research & Development
|
Tax withholdingCommon Stock | 540 | $32.33 | $17,458.20 |
DisclosureSEC source: 0001104659-22-055430 · tm2214297-4_4seq1.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,736 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:40 UTC |
Milligan SandraHead of Research & Development
|
Exercise / conversionCommon Stock | 1,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055430 · tm2214297-4_4seq1.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055427 · tm2214297-2_4seq1.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219 Underlying: Common Stock · 1,219 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 418 | $32.33 | $13,513.94 |
DisclosureSEC source: 0001104659-22-055427 · tm2214297-2_4seq1.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,170 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 1,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055427 · tm2214297-2_4seq1.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC |
Ali KevinChief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 2,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055425 · tm2214297-1_4seq1.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,709 Underlying: Common Stock · 2,709 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC |
Ali KevinChief Executive Officer
|
Tax withholdingCommon Stock | 1,523 | $32.33 | $49,238.59 |
DisclosureSEC source: 0001104659-22-055425 · tm2214297-1_4seq1.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,648 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC |
Ali KevinChief Executive Officer
|
Exercise / conversionCommon Stock | 2,709 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055425 · tm2214297-1_4seq1.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:05 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 44,091 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042357 · tm2211465-3_4seq1.xml · derivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,091 Underlying: Common Stock · 44,091 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:05 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 14,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042357 · tm2211465-3_4seq1.xml · derivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,314 Underlying: Common Stock · 14,314 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:14 UTC |
DiMarco KathrynCorporate Controller
|
GrantRestricted Stock Units · Derivative | 12,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042368 · tm2211465-11_4seq1.xml · derivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,882 Underlying: Common Stock · 12,882 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:13 UTC |
Telman Deborah HGen Counsel & Corp Sec
|
GrantStock Option (right to buy) · Derivative | 39,682 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042366 · tm2211465-10_4seq1.xml · derivative · entry 2 Telman Deborah H · CIK 0001860008 · Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,682 Underlying: Common Stock · 39,682 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:13 UTC |
Telman Deborah HGen Counsel & Corp Sec
|
GrantRestricted Stock Units · Derivative | 12,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042366 · tm2211465-10_4seq1.xml · derivative · entry 1 Telman Deborah H · CIK 0001860008 · Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,882 Underlying: Common Stock · 12,882 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:11 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 71,649 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042363 · tm2211465-8_4seq1.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,649 Underlying: Common Stock · 71,649 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:11 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 23,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042363 · tm2211465-8_4seq1.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,260 Underlying: Common Stock · 23,260 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:12 UTC |
Stahler Rachel AChief Information Officer
|
GrantStock Option (right to buy) · Derivative | 33,068 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042365 · tm2211465-9_4seq1.xml · derivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,068 Underlying: Common Stock · 33,068 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:12 UTC |
Stahler Rachel AChief Information Officer
|
GrantRestricted Stock Units · Derivative | 10,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042365 · tm2211465-9_4seq1.xml · derivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,735 Underlying: Common Stock · 10,735 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:10 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
GrantStock Option (right to buy) · Derivative | 17,636 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042362 · tm2211465-7_4seq1.xml · derivative · entry 2 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,636 Underlying: Common Stock · 17,636 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:10 UTC |
Ritter Geralyn SHd of Ext. Affairs and ESG
|
GrantRestricted Stock Units · Derivative | 5,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042362 · tm2211465-7_4seq1.xml · derivative · entry 1 Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,725 Underlying: Common Stock · 5,725 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:09 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantStock Option (right to buy) · Derivative | 26,455 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042361 · tm2211465-6_4seq1.xml · derivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,455 Underlying: Common Stock · 26,455 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:09 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantRestricted Stock Units · Derivative | 8,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042361 · tm2211465-6_4seq1.xml · derivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,588 Underlying: Common Stock · 8,588 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:07 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantStock Option (right to buy) · Derivative | 36,375 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042360 · tm2211465-5_4seq1.xml · derivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,375 Underlying: Common Stock · 36,375 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:07 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantRestricted Stock Units · Derivative | 11,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042360 · tm2211465-5_4seq1.xml · derivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,809 Underlying: Common Stock · 11,809 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:06 UTC |
Milligan SandraHead of Research & Development
|
GrantStock Option (right to buy) · Derivative | 55,114 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042359 · tm2211465-4_4seq1.xml · derivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,114 Underlying: Common Stock · 55,114 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:06 UTC |
Milligan SandraHead of Research & Development
|
GrantRestricted Stock Units · Derivative | 17,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042359 · tm2211465-4_4seq1.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:04 UTC |
Falcione AaronChief Human Resources Officer
|
GrantStock Option (right to buy) · Derivative | 33,068 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042354 · tm2211465-2_4seq1.xml · derivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,068 Underlying: Common Stock · 33,068 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:04 UTC |
Falcione AaronChief Human Resources Officer
|
GrantRestricted Stock Units · Derivative | 10,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042354 · tm2211465-2_4seq1.xml · derivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,735 Underlying: Common Stock · 10,735 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:02 UTC |
Ali KevinChief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 198,412 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042353 · tm2211465-1_4seq1.xml · derivative · entry 2 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,412 Underlying: Common Stock · 198,412 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:02 UTC |
Ali KevinChief Executive Officer
|
GrantRestricted Stock Units · Derivative | 64,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042353 · tm2211465-1_4seq1.xml · derivative · entry 1 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,414 Underlying: Common Stock · 64,414 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:47 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029458 · tm228175-6_4seq1.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,718 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:47 UTC |
Fiedler SusanneChief Commercial Officer
|
Tax withholdingCommon Stock | 4,098 | $37.57 | $153,961.86 |
DisclosureSEC source: 0001104659-22-029458 · tm228175-6_4seq1.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:47 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionCommon Stock | 8,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029458 · tm228175-6_4seq1.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:47 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 3,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029459 · tm228175-7_4seq1.xml · derivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,486 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:47 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 1,278 | $37.57 | $48,014.46 |
DisclosureSEC source: 0001104659-22-029459 · tm228175-7_4seq1.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,693 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:47 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 3,486 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029459 · tm228175-7_4seq1.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC |
Milligan SandraHead of Research & Development
|
Exercise / conversionRestricted Stock Units · Derivative | 10,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029457 · tm228175-5_4seq1.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,171 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC |
Milligan SandraHead of Research & Development
|
Tax withholdingCommon Stock | 2,941 | $37.57 | $110,493.37 |
DisclosureSEC source: 0001104659-22-029457 · tm228175-5_4seq1.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,380 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.